IRVINE,
CA--(Marketwired - Jul 20, 2016) - Cannabis
Science, Inc. (
Key CBIS market growth indicators propel the Company into the first half of 2016:
- The Company applauded
legislators in seeking to improve access to
cannabis for medical purposes, and the DEA for
initiating a review on its scheduling of
marijuana. Market could potentially open up
approximately 10 - 100 times to well over US$300
Billion based on streamlined FDA clinical trials
access and increased pre-clinical study
acceptances.
- Historic November voting
in California could see a market increase of 100 -
1,000 times based on relaxed laws for adult to
access medical marijuana based on age specific
regulations. This California move could
potentially drive the Cannabis industry to well
over US$750 Billion. In due time, the industry
could see a steady healthy growth curve across
America thus ringing in the Country's newest
Trillion-dollar industry.
- This sets the stage for
a breakout year for the Company as the market
expands. Each year will expand our success. Even
at a minimal 1% market capture rate, the Company
could rapidly see a combined influx of revenues
that can instantly change the face of the company
forever. CBIS sets this stage for high-growth
amidst DEA historical national industry changes
for critical ailment treatments & historic
California voting in November.
- In preparation for this
explosive growth CBIS, Inc. has relocated its
headquarters to Irvine, California to be closer to
suppliers, distributers, and our strategic
partners. The Company is negotiating for a Los
Angeles area laboratory/medical clinic. CBIS, Inc.
has initiated pre-clinical trials for five (5)
critical drugs targeting cancer, HIV/AIDS, and a
number of endemic neurological disorders. Our
cannabinoid portfolio is extensive and we are
currently creating coherent drug development
programs for each active cannabinoid set.
- The landmark California
lab expansions will ignite laboratory progress
with its partner IGXBio's GenePro FDA
Investigational New Drug (IND) Number 015982 for
further drug development to identify & develop
agonist cannabinoids for GenePro.
- CBIS applauds the recent
success of GW Pharmaceuticals in their phase three
testing of a CBD-based product designed to treat
patients with a rare form of epilepsy. The
successful trials in Europe help pave the way for
companies like Cannabis Science to move forward
with their own testing in Europe and in the United
States. It will also allow for a quicker
regulatory process due to more research being made
available for regulators and more experience with
these types of treatments.
- "We couldn't be happier
with GW Pharmaceutical's success today. As these
positive results continue to be found in pivotal
studies, public and regulatory perception opens up
to the effectiveness of CBD in treating disease,
both physically and mentally," said Cannabis
Science, Inc. President & CEO, Co-Founder,
Raymond C. Dabney. Cannabis Science is working
diligently to continue testing and providing
limited rollouts for its own CBD-based treatment
products in California at the moment. On the heels
of GW Pharmaceuticals' success, the Company is
more confident than ever in its planned wide-scale
rollout, which will include a wider array of near
term clinical drug development programs in
California, possibly Washington, and the
Netherlands.
- The new laboratory can
open the markets dramatically for the Company's
proprietary cannabinoid formulations being created
to be distributed nationwide. The urgent objective
is the treatment of critical ailments, such as
various cancers, HIV/AIDS, pain management,
autism, PTSD, and other neurological conditions.
Though this list represents only a handful of the
targeted ailments we hope to treat, it reflects
some of the serious medical afflictions we are
dealing with. The Company fully understands that
while the price is high, one blockbuster
pharmaceutical drug can change the framework
forever in Cannabis Science, and the Company
believes it has more than one.
- Mr. Raymond C. Dabney,
President, Chief Executive Officer, and Co-Founder
of Cannabis Science, Inc., has accepted an
invitation to serve as a Co-Chair of this year's
Ronald H. Brown African Affairs Series organized
by the Constituency for Africa (CFA). The theme of
this year's event, scheduled from September
12-17th, 2016 in Washington, DC, "Setting the
US-Africa Agenda for the Next Administration."
- In May 2016 CBIS African
healthcare infrastructure delegation led by Mr.
Raymond Dabney and including Dr. Julius Garvey,
member of the Scientific Advisory Board of CBIS,
Dr. Allen Herman, Chief Medical Officer of CBIS,
and Mr. Melvin Foote, President & CEO of
Constituency for Africa has just concluded with
outstanding results. Beginning in Cape Town, South
Africa, the CBIS delegation met with key
stakeholders in Government Ministries, political
parties, the private sector, civil society, and
academia. CBIS discussed and planned collaboration
with international regulatory agencies in South
Africa and Namibia to provide access to high
quality, first-class cannabinoid pharmaceuticals
to those critically in need of new treatments for
life threatening and debilitating conditions.
- The CBIS delegation has
met the prime objectives of the trip to South
Africa and is now planning the next steps and trip
for a follow up implementation program. The
delegation, educational leaders, and the various
government entities discussed the critical role
that the Raymond C. Dabney University (RCDU) will
play in education, job creation, and in the
development of effective cannabinoids and other
phyto-pharmaceuticals for the many critical
ailments that are endemic in the region.
- "Our visit to southern
Africa, which also marked my first visit to
Africa, was successful, rich, and fulfilling. The
people and leaders of Namibia and South Africa
showed us remarkable generosity and we know that
our collaboration with the extraordinary
institutions and people of the region will result
in sustainable drug development, research,
educational programs, and job creation covering
the basic areas of economic development one step
at a time across the vast continent of Africa,"
commented Mr. Dabney.
- The Company signed its
first Native American property development deal
for 10-acres partnering with RCDU for a total of
40-acres to be developed in Fort McDermitt, which
will provide legal education, new drug research,
plenty of jobs, and cultivation opportunities for
the tribal members. Revenue boost is the secondary
gain here even though it's moderately projected
over US$100 Million for the project. The
additional educational, community and economic
development opportunities provided by the
partnership with our university and the Native
American tribe is profound, and sets the stage for
sustainable drug development.
- Cannabis Science will
host a black tie, red carpet Gala event in Los
Angeles, entitled "Cannabis Kills Cancer."
Celebrities, patients, scientists, physicians, and
shareholders are expected to attend. The event is
intended to raise funds for cannabis-focused
cannabis research. Mr. Dabney will reveal his
loyalty gift share program at the Gala event while
highlighting historical breakthroughs the Company
has achieved during its first 7 years of
operations in the cannabis industry. This Gala
Event will set the stage for the Company to raise
"Millions of Dollars to Continue the Fight" by
expanding its treatment base targeting critical
ailments. The funds raised will go to expand
current clinical studies the Company has under way
targeting cancer, HIV/AIDS, sleep disorders, pain
management, PTSD, autism, and many more critical
ailments.
- Cannabis Science
executives attended several major events for
preparation, including the amfAR Gala 2015, NYC,
and several other industry events where the
company was able to focus on networking, meet with
its current distributors and suppliers, and thank
its expanding patient-base in person. Several new
CBD, oil (PDCO), and both Indica and Sativa
capsule products were developed and entered into
cannabis events, where they performed well and
impressed judging panels.
- Cannabis Science
products can be purchased in dispensaries
throughout the state of California as well as in
some in Colorado. The company partnered with
Purple Haze Properties (owned by a brother of Jimi
Hendrix). Jimi's Meds products can be ordered
online by patients in California as well.
Developed Jimi's Meds, a Jimi Hendrix-inspired and
branded medical cannabis product line.
- The company's European Subsidiary, Cannabis Science Europe GmbH., launched the world's first high-quality cannabis-based instant drink mix, CannaPOW. In order to produce a premium instant cannabis drink mix, the company had to discover a method of protecting cannabinoids from oxidation. Launched in Germany, the Company is now negotiating with distributors to immediately bring CannaPOW to North America.
"As the political tides turn and the market breaks wide-open allowing the cannabis industry to peek its head into daylight, look out as the gates open, they might be bursting at the seams. We are living in very exciting times in this industry, we are creating Greatness and we are ALL making History, we should all be very proud! We are moving rapidly and deliberately into well-considered research opportunities and new strategic partnerships. We have emerged at this point because scientists, physicians, and patients increasingly understand that cannabinoids as treatment options have a strong basis in biology and the actions of critical cannabinoid drug moieties are closely allied with the body's own endo-cannabinoid system. The best is yet to come, and once our laboratory is up and running, we can bring our critical ailment drugs to the market much faster on a much wider basis," said Dabney. "We are very happy with the first half of 2016, but we are even more optimistic about the second half."
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of a unique understanding of biologic processes to provide novel treatment approaches for common ailments and for those disorders where current treatments are relatively unsuccessful and understanding remain incomplete. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the increasingly complex underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward Looking & Disclaimer / Privacy
Splitting Molecules - New
Technologies Propel Stock Upward On News
Top Stock Alerts - Target Price
Raised - NASDAQ Listed Stock Doubles in 2 Weeks
Dave Donlin Video Interview With
Gain Clients GCLT OTC
High Volume Alert GCLT - OTC -
New Target Price Set